Search hospitals > Ontario > OTTAWA
Ottawa Hospital Research Institute
Claim this profileOTTAWA, Ontario K1H 8L6
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Colorectal Cancer
219 reported clinical trials
26 medical researchers
Summary
Ottawa Hospital Research Institute is a medical facility located in OTTAWA, Ontario. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer and other specialties. Ottawa Hospital Research Institute is involved with conducting 219 clinical trials across 274 conditions. There are 26 research doctors associated with this hospital, such as John Hilton, MD, Dar Dowlatshahi, MD, Scott A Laurie, and Scott C. Morgan.Area of expertise
1Cancer
Global LeaderTP53 positive
Stage IV
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
John Hilton, MDOttawa Hospital Research Institute8 years of reported clinical research
Studies Breast Cancer
Studies Tumors
13 reported clinical trials
34 drugs studied
Dar Dowlatshahi, MDOttawa Hospital Research Institute4 years of reported clinical research
Studies Stroke
Studies Bleeding
7 reported clinical trials
12 drugs studied
Scott A LaurieThe Ottawa Hospital3 years of reported clinical research
Studies Tumors
Studies Solid Tumors
6 reported clinical trials
12 drugs studied
Scott C. MorganOttawa Hospital Research Institute4 years of reported clinical research
Studies Prostate Cancer
Studies Renal Cell Carcinoma
5 reported clinical trials
22 drugs studied
Clinical Trials running at Ottawa Hospital Research Institute
Bleeding
Prostate Cancer
Melanoma
Non-Small Cell Lung Cancer
Multiple Myeloma
Lymphoma
Skin Cancer
Plasma Cell Neoplasms
Stroke
Cancer
Lower INR Warfarin
for Mechanical Valve Patients
This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.
Recruiting2 awards Phase 33 criteria
Aggressive Blood Pressure Management
for Brain Hemorrhage
The vast majority of intracerebral hemorrhage (ICH) patients present with elevated blood pressure(BP). Management of BP is controversial with two competing rationales. There is some evidence that hyperacute treatment may improve outcomes by reducing the rate of hematoma expansion. Physicians have been reluctant to reduce BP early after ICH onset, fearing reduced cerebral blood flow (CBF) will increase ischemia and increase the risk of further damage. Other confounding mediators to further ischemic injury following ICH include increased platelet activity, withdrawal of antithrombotic therapy, endothelial dysfunction, inflammation and hypercoagulability. This study is phase II of the ICH-ADAPT study. The investigators hypothesize that aggressive antihypertensive therapy will alter the natural history of heamatoma growth, improving outcomes after Intracranial Hemorrhage (ICH). The previous phase I ICH-ADAPT study has established the safety of early BP treatment. The investigators have designed a phase II study in which ICH patients are randomized to aggressive versus conservative BP treatment using a deferred consent procedure. An adaptive randomization will be used to treat BP to \< 140 mmHg SBP or \< 180 mmHg SBP. Treatment must be implemented as soon as possible after radiological confirmation of diagnosis. Antihypertensive therapy must begin within 6 hours of symptom onset. The patient will be re-imaged 24 hours later. The patient will have continuous non-invasive BP and heart rate(HR) monitoring for a minimum of 24 hours. Antihypertensive drug use and dosage will be recorded with BP and HR. Patients will be monitored regularly until study completion. MRI's will be done at 48 hours, day 7 and day 30. This imaging will help to detect ischemic changes that may occur. Blood will be collected at the same time as the MRI. Blood analysis will be done to possibly identify biomarkers that may be putative mediators of ischemic injury in ICH patients.
Recruiting1 award Phase 24 criteria
rFVIIa
for Hemorrhagic Stroke
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
Recruiting1 award Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ottawa Hospital Research Institute?
Ottawa Hospital Research Institute is a medical facility located in OTTAWA, Ontario. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer and other specialties. Ottawa Hospital Research Institute is involved with conducting 219 clinical trials across 274 conditions. There are 26 research doctors associated with this hospital, such as John Hilton, MD, Dar Dowlatshahi, MD, Scott A Laurie, and Scott C. Morgan.